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BIOMIMETIC PORE STRUCTURES AND METHODS OF MAKING BIOMIMETIC
PORE STRUCTURES
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of and priority to U.S. Provisional Application
Serial No. 62/080,082, having the title "Urea-Templated Materials," filed on November 14,
2014, the disclosure of which is incorporated herein in by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
This invention was made with Government support under contract DMR 0805298
awarded by the National Science Foundation. The Government has certain rights in the
invention.
BACKGROUND
Tissues in the body are hierarchically structured composite materials with
tissue-specific properties. Although it is possible to employ 3D printing technologies to
prepare porous materials, it is challenging to fabricate porous structures accurately mimicking
native tissues. Thus, there is a need to overcome difficulties in known methods or find
alternatives.
SUMMARY
Embodiments of the present disclosure provide for tissue scaffolds, biodegradable
porous tissue scaffolds, biodegradable electroactive tissue scaffolds, biodegradable
electroactive porous tissue scaffolds, methods of makes each type of tissue scaffold, methods
of using each type of tissue scaffold, and the like.
An embodiment of the present disclosure provides for a method of forming a tissue
scaffold, among others, that includes: mixing a solution including urea and a non-aqueous
solvent with a polymer that is soluble with the solvent to form a mixture; disposing the
mixture on a substrate; and removing the solvent from the mixture to form a tissue scaffold.
In an embodiment, the method can also include: removing the urea from the tissue scaffold to
form a biodegradable porous tissue scaffold, wherein removal of the urea forms pores within
the tissue scaffold to form the biodegradable porous tissue scaffold. In an embodiment, the
non-aqueous solvent can be: formic acid, trifluoroacetic acid, hexafluoroisopropanol,
hexafluoroacetone hydrate, methanol, ethanol, propanol, isopropanol, acetophenone,
methoxyethanol, ethanediol, 1,2-propanediol, 1,3-propanediol, glycerol, glycerol
monoacetate, glycerol diacetate, methylacetate, ethylacetate, allyl alcohol, furfuryl alcohol,
diacetone alcohol, benzyl alcohol, cyclohexanol or a combination thereof. In an embodiment,
the polymer is selected from the group consisting of: nylon, hydroxybutyric acids,
polyanhydrides, polphosphazenes, polyphosphoesters, polyethers, polysilanes, polysiloxanes,
polyurethanes,) polycaprolactone, polyesters, polyamides, PCL, PLLA, PLGA, lignins,
polyalanine, oligoalanine, collagen, silk, cellulose, chitin, chitosan, dextran, or a combination
thereof.
In an embodiment, the method can include an electroactive tissue scaffold by
polymerizing an electroactive polymer with the tissue scaffold. In an embodiment, the
method can include removing the urea from the electroactive tissue scaffold to form a
biodegradable electroactive porous tissue scaffold, wherein removal of the urea forms pores
within the tissue scaffold to form the biodegradable electroactive porous tissue scaffold. In
an embodiment, the electroactive polymer can be: polypyrrole, polyaniline, polythiophene,
poly(3,4-ethylenedioxythiophene), poly fluorenes, polyphenylenes, polypyrenes,
polyazulenes, polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s,
poly(p-phenylene vinylene)s, polyfurans, or a combination thereof.
In an embodiment, the substrate can includes a network of channels, wherein the
mixture is disposed in the network of channels, wherein the method further includes:
removing the substrate to form the tissue scaffold having a network of pores extending
through the tissue scaffold. The network of channels are aligned relative to one another and
each of the channels in the network of channels has a diameter of about 50 nm to 100 µιη and
the length of about 1 cm to 10 cm. In an embodiment, the method also includes removing the
urea from the tissue scaffold to form a biodegradable porous tissue scaffold, wherein removal
of the urea forms pores within the tissue scaffold to form the biodegradable porous tissue
scaffold.
In an embodiment, the pores formed from removal of the urea are of the type selected
from the group consisting of: dendritic, linear, and a combination thereof.
An embodiment of the present disclosure includes a structure, among others, that
includes: a tissue scaffold including a polymer and urea, wherein the polymer is soluble in a
non-aqueous solvent selected from the group consisting of: formic acid, trifluoroacetic acid,
hexafluoroisopropanol, hexafluoroacetone hydrate, methanol, ethanol, propanol, isopropanol,
acetophenone, methoxyethanol, ethanediol, 1,2-propanediol, 1,3 -propanediol, glycerol,
glycerol monoacetate, glycerol diacetate, methylacetate, ethylacetate, allyl alcohol, furfuryl
alcohol, diacetone alcohol, benzyl alcohol, cyclohexanol and a combination thereof. In
addition, the structure can include an electroactive polymer. The urea is in the form of urea
crystals, wherein the urea crystals have a crystal structure selected from the group consisting
of: dendritic, linear, or a combination thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
Many aspects of the present disclosure can be better understood with reference to the
following drawings.
Figure 1.1 demonstrates hydrogen bond mediated self-assembly of supracolloidal
assemblies of urea that act as sacrificial templates to impart pores in biomaterials.
Figures 1.2A-D are brightfield microscope images of urea crystals. (1.2A) Formed by
uncontrolled crystallization from solutions of urea in formic acid (scale bar, 200 µιη); (1.2B)
Formed by uncontrolled crystallization from solutions of urea in hexafluoroacetone hydrate
(scale bar, 200 µιη); (1.2C) Formed by uncontrolled crystallization from solutions of urea in
hexafluoroisopropanol (scale bar, 200 µιη); and (1.2D) Formed by controlled crystallization
from solutions of urea in hexafluoroisopropanol in a Pasteur pipette (scale bar, 500 µιη) .
Figures 1.3A-F are images of urea crystal-templated silk films. (1.3A) Brightfield
microscope image of urea crystal-templated silk films from solution in formic acid (scale bar,
600 µιη); (1.3B) SEM image of urea crystal-templated silk films formed from solution in
formic acid (scale bar, 200 µιη); (1.3C) Brightfield microscope image of urea crystal-
templated silk films formed from solution in hexafluoroacetone hydrate (scale bar, 600 µιη);
(1.3D) SEM image of urea crystal-templated silk films formed from solution in
hexafluoroacetone hydrate (scale bar, 100 µιη); (1.3E) SEM image of urea crystal-templated
silk films formed from solution in hexafluoroisopropanol (scale bar, 100 µιη); and (1.3F)
SEM image of urea crystal-templated silk films formed from solution in water (scale bar, 100
µιη) . Images are representative of at least 3 locations on 3 samples.
Figure 1.4 is an image of fibroblasts on the surface of the porous silk substrates stained
with DAPI (nuclei) and Alexa Fluor 488® Phalloidin (actin filaments); scale bar, 100 µιη.
Images are representative of at least 3 locations on 3 samples.
Figure 2.1 is a hydrogen bond-mediated self-assembly of urea.
Figures 2.2A-D demonstrate the template manufacture process. (2.2A) Illustration of
the experimental setup used to produce the hard acrylic master template with grooves with
widths and heights of 2 mm. (2.2B) Examples of the hard acrylic master templates produced:
(left) grooves with widths and heights of 2 mm; (center) grooves with widths and heights of 1
mm; (right) grooves with widths and heights of 0.5 mm. (2.2C) Examples of the flexible
PDMS templates produced: (left) grooves with widths and heights of 2 mm; (right) grooves
with widths and heights of 1 mm. (2.2D) Illustration of the experimental setup using the
flexible, grooved PDMS template covered with a glass slide, which facilitates controlled
solvent evaporation and thereby preferential alignment of urea crystals within the grooves.
Figure 2.3 is an experimental setup for electrical stimulation of electroactive PCL-
based tissue scaffolds (not to scale). (CE) counter electrode. (CT) copper tape. (PCL)
electroactive PCL-based tissue scaffolds. (PCW) polycarbonate well. (RE) reference
electrode. (WE) working electrode.
Figures 2.4A-D are scanning electron microscope images of sections of PCL-based
tissue scaffolds with aligned pores. (2.4A) Millimeter and micrometer scale topography of
non-electroactive scaffolds, scale bar represents 500 µιη. (2.4B) Micrometer and nanometer
scale topography of non-electroactive scaffolds, scale bar represents 10 µιη. (2.4C)
Millimeter and micrometer scale topography of electroactive scaffolds, scale bar represents
500 µιη. (2.4D) Micrometer and nanometer scale topography of electroactive scaffolds
showing evidence of increased nanometer scale surface roughness due to the presence of an
interpenetrating network of PPy and PSS interwoven within the PCL matrix, scale bar
represents 10 µιη.
Figures 2.5A-D demonstrates spectroscopic analysis of PCL-based tissue scaffolds. (2.5A
and 2.5B) FTIR spectra of PCL-based tissue scaffolds with aligned pores: (2.5A) non-
electroactive scaffolds, (2.5B) electroactive scaffolds. Peaks observed at ca. 1543 and ca.
1480 c 1 are characteristic of the antisymmetric and symmetric ring stretching modes of
pyrrole [65,78]. (C and D) XPS spectra of PCL-based tissue scaffolds with aligned pores:
(2.5C) non-electroactive scaffolds, (2.5D) electroactive scaffolds. Peaks at ca. 400 eV (N Is)
and ca. 168 eV (S 2p) are characteristic of PPy and PSS, respectively [65,79].
Figure 2.6A-B are in vitro degradation profiles of the PCL-based tissue scaffolds in
PBS. (2.6A) Non-electroactive scaffolds: black circles in the absence of cholesterol esterase;
grey circles in the presence of cholesterol esterase. (2.6B) Electroactive scaffolds: black
circles in the absence of cholesterol esterase; grey circles in the presence of cholesterol
esterase. Error bars represent standard deviations.
Figures 2.7A-B show that cells respond to the topography of the PCL-based tissue
scaffolds substrates and align on the substrates. (2.7A) Schwann cells on non-electroactive
scaffolds (scale bar represents 50 µηι); (2.7B) Schwann cells on electroactive scaffolds
without electrical stimulation (scale bar represents 50 µιη) .
Figure 2.8 graphs the concentration of Schwann cell-produced NGF in the culture
medium. Black circles) commercially available tissue-culture treated Corning® Costar® tissue
culture plates. (Red circles) non-electroactive PCL-based tissue scaffolds. (Yellow circles)
electroactive PCL-based tissue scaffolds without electrical stimulation. (Blue circles)
electroactive PCL-based tissue scaffolds with electrical stimulation. Error bars represent
standard deviations.
DETAILED DESCRIPTION
This disclosure is not limited to particular embodiments described, and as such may,
of course, vary. The terminology used herein serves the purpose of describing particular
embodiments only, and is not intended to be limiting, since the scope of the present
disclosure will be limited only by the appended claims.
Where a range of values is provided, each intervening value, to the tenth of the unit of
the lower limit unless the context clearly dictates otherwise, between the upper and lower
limit of that range and any other stated or intervening value in that stated range, is
encompassed within the disclosure. The upper and lower limits of these smaller ranges may
independently be included in the smaller ranges and are also encompassed within the
disclosure, subject to any specifically excluded limit in the stated range. Where the stated
range includes one or both of the limits, ranges excluding either or both of those included
limits are also included in the disclosure.
As will be apparent to those of skill in the art upon reading this disclosure, each of the
individual embodiments described and illustrated herein has discrete components and features
which may be readily separated from or combined with the features of any of the other
several embodiments without departing from the scope or spirit of the present disclosure.
Any recited method may be carried out in the order of events recited or in any other order that
is logically possible.
Embodiments of the present disclosure will employ, unless otherwise indicated,
techniques of organic chemistry, biochemistry, microbiology, molecular biology,
pharmacology, medicine, and the like, which are within the skill of the art. Such techniques
are explained fully in the literature.
Prior to describing the various embodiments, the following definitions are provided
and should be used unless otherwise indicated.
Unless otherwise defined, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art of microbiology,
molecular biology, medicinal chemistry, and/or organic chemistry. Although methods and
materials similar or equivalent to those described herein can be used in the practice or testing
of the present disclosure, suitable methods and materials are described herein.
As used in the specification and the appended claims, the singular forms "a," "an,"
and "the" may include plural referents unless the context clearly dictates otherwise. Thus, for
example, reference to "a support" includes a plurality of supports. In this specification and in
the claims that follow, reference will be made to a number of terms that shall be defined to
have the following meanings unless a contrary intention is apparent.
Discussion :
Embodiments of the present disclosure provide for tissue scaffolds, biodegradable
porous tissue scaffolds, biodegradable electroactive tissue scaffolds, biodegradable
electroactive porous tissue scaffolds, methods of makes each type of tissue scaffold, methods
of using each type of tissue scaffold, and the like.
In an embodiment of the present disclosure a sacrificial biodegradable material (e.g.,
urea crystals) can be removed from a tissue scaffold to form a porous tissue scaffold.
Removal of sacrificial material from a matrix is a comparatively low cost alternative that
allows the generation of hierarchically organized pores in the tissue scaffold. Selection of
non-aqueous solvents can be used to expand the scope of polymers that are compatible with,
while selection of non-aqueous solvents in conjunction with specific polymers allow control
of the topography (e.g., type (e.g., linear, dendritic, or a combination thereof) and dimensions
(e.g., on the nanoscale) of the pores) of the tissue scaffold. Embodiments of the present
disclosure discuss the role of solvent interactions on the morphology of the resulting
supracolloidal crystals. In particular, embodiments of the present disclosure can be used to
prepare silk (e.g., B. mori silk) protein-based biomaterials with pores that cells (e.g., human
dermal fibroblasts, Schwann cells, and the like) respond to by aligning with the long axis of a
network of macroscale pores. Embodiments of the present disclosure can be used in tissue
engineering in which cell alignment is observed, including skin, bone, muscle and nerve.
Additional details are provided herein and in the Examples.
In an embodiment, the tissue scaffolds can be made so that they also have
electroactive properties that can allow for electrical stimulation of, for example, cells cultured
on the tissue scaffolds. The electrical stimulation can be applied periodically. In a particular
embodiment, a cell and/or tissue can be incubated with the electroactive tissue scaffold and
cultured in an appropriate medium so that the cells are stimulated. In an embodiment, the
electrical stimulation increased the production of nerve growth factor (NGF) to more than
three times the amount produced by non-stimulated cells, which may improve clinical
outcomes during peripheral nerve regeneration. Additional details are provided herein and in
the Examples.
In an embodiment, tissue scaffolds of the present disclosure can be used to deliver
agents such as drugs, antibacterial agents, and antifungal agents.
An embodiment of the present disclosure includes forming a tissue scaffold. In an
embodiment, the method includes mixing a solution including urea (i.e., CO(NH2)2) and a
non-aqueous solvent with a polymer that is soluble with the solvent to form a mixture. The
ratio of the amount of polymer to urea can be about 99 to 1 or about 1 to 4. The mixture is
disposed on a substrate and then the solvent is removed from the mixture in a controlled or
uncontrolled manner. Uncontrolled evaporation of the solvent typically results in crystals not
being aligned, whereas, by controlling evaporation such that solvent preferentially evaporates
from one or more specific positions it is possible to initiate the crystallization of urea to yield
long, directionally aligned crystals. The urea crystals formed can be of the dendritic type,
linear type, or a combination thereof. The type and dimensions (e.g., nanoscale (e.g., about
50 nm to 500 µιη or about 1 to 500 µιη)) of the urea crystals formed can be controlled by
selection of the non-aqueous solvent and the polymer.
Subsequently, the urea crystals can be removed from the tissue scaffold to form a
biodegradable porous tissue scaffold. Removing the urea crystals forms pores within the
tissue scaffold, where the pores have nanoscale dimensions and are separate from the network
of pores described shortly which are of the microscale. The pores formed from removal of
the urea crystals are of the types: dendritic, linear, and a combination thereof. Additional
details are described in the Examples.
In an embodiment, the polymer is insoluble or sparingly soluble (<0. 1 mg ml 1) in
water. The polymer is soluble in a non-aqueous solvent such as formic acid, trifluoroacetic
acid, hexafluoroisopropanol, hexafluoroacetone hydrate, methanol, ethanol, propanol,
isopropanol, acetophenone, methoxyethanol, ethanediol, 1,2-propanediol, 1,3 -propanediol,
glycerol, glycerol monoacetate, glycerol diacetate, methylacetate, ethylacetate, allyl alcohol,
furfuryl alcohol, diacetone alcohol, benzyl alcohol, cyclohexanol and a combination thereof.
The polymer can include a synthetic polymer (e.g., polyesters, polyamides,
polyurethanes, PCL, PLLA, PLGA, nylon, hydroxybutyric acids, polyanhydrides,
polphosphazenes, polyphosphoesters, polyethers, polysilanes, polysiloxanes or pellethane), a
natural polymer (e.g. proteins, polysaccharides, lignins, polyalanine, oligoalanine, collagen,
silk, cellulose, chitin, chitosan, or dextran), or a combination thereof. In an embodiment, the
tissue scaffold can include a mixture of different types of polymers (e.g., a portion of
polycaprolactone polymer and another polyester).
In an embodiment, an electroactive polymer can be included in the tissue scaffold. In
an embodiment the electroactive polymer can be added to the tissue scaffold after the
polymer is mixed with the urea to form the tissue scaffold or the electroactive polymer,
polymer, and urea can be mixed together prior to forming the tissue scaffold. Introduction of
the electroactive polymer to the tissue scaffold can produce an electroactive tissue scaffold
and removal of the urea can result in the formation of an electroactive porous tissue scaffold.
In this regard, embodiments of the present disclosure include tissue scaffolds (e.g.,
biodegradable electroactive tissue scaffolds, biodegradable electroactive porous tissue
scaffolds) that include a polymerizable electrically responsive unit (e.g., pyrrole) that is
attached by polymerization (e.g., covalently, non-covalently, or as an interpenetrating
network) within the polymer matrix (e.g., polycaprolactone matrix) in order to form an
electroactive tissue scaffold upon which cells or tissues can be cultured. In an embodiment,
the micro- and nano-topological features (e.g., grooves, pores, bumps or other topological
features) of the matrix can be preserved during polymerization with the unit. In an
embodiment, electroactive tissue scaffolds can also be used as electroactive actuators capable
of mechanotransduction of cells such as stem cells.
In an embodiment, the electroactive polymer (conducting polymer) can include
polymers such as polypyrrole, polyaniline, polythiophene, poly(3,4-ethylenedioxythiophene),
poly fluorenes, polyphenylenes, polypyrenes, polyazulenes, polynapthalenes, polyindoles,
polyazepines, poly(p-phenylene sulfide)s, poly(p-phenylene vinylene)s, and polyfurans. In an
embodiment, there are biodegradable versions, in which there are block of conducting units
within a polymer chain containing biodegradable bonds (e.g. esters and amides), that can also
be used as the conducting polymer. In an embodiment, the electroactive polymer can be used
in conjunction with a dopant. The dopant can be a polymer that has the opposite charge to
the conducting polymer, and can be low molecular weight (e.g., chlorine ions, tosylate ions,
and the like) or high molecular weight (e.g., collagen, hyaluronic acid, and the like).
In an embodiment, the electroactive polymer can be about 1 to 99 or about 2 to 10
weight percent of the tissue scaffold.
As mentioned above, the mixture is disposed on a substrate. In an embodiment, the
substrate can be flat or can have contours (e.g., to form topographic features in or through the
tissue scaffold). In an embodiment, the substrate can be used to form a network of pores or
channels that extend through the width of the tissue scaffold. In addition the network of
channels can be aligned relative to one another, which can be achieved by controlled
evaporation of the solvent from the mixture (polymer/urea solution), thereby initiating
directional crystallization of the urea. In an embodiment, the substrate can include a network
of channels and areas outside of the network of channels. The mixture can be disposed in the
network of channels but not on the areas outside of the network of channels. The mixture can
be dried and the tissue scaffold formed according to the topography of the substrate so that a
network of pores extends through the tissue scaffold. In an embodiment, each of the pores in
the network of pores has a diameter, if spherical, or other dimension if not spherical, of about
10 nm to 500 µιη or about 50 nm to 100 µιη and has a length through the tissue scaffold (or
the width of the tissue scaffold) of about 1cm to 10 cm or about 0.5 cm to 3 cm. In an
embodiment, the tissue scaffold has pore as a result of the structure and as a result of the
removal of the urea crystals.
Having described embodiments of making tissue scaffolds, additional details
regarding tissue scaffolds are now described. As mentioned above, various types of tissue
scaffolds have been disclosed including: biodegradable porous tissue scaffolds, biodegradable
electroactive tissue scaffolds, biodegradable electroactive porous tissue scaffolds, and the
like. The term "biodegradable" refers to polymers that degrade through the action of a
physicochemical (e.g., hydrolysis, pH) or biological (e.g., enzyme) trigger that the polymer is
exposed to in use.
An embodiment of the tissue scaffold includes a tissue scaffold including the polymer
and urea, wherein the polymer is not soluble in water. In this embodiment the urea has not
yet been removed. Once the urea is removed, the tissue scaffold can be porous due to the
removal of the urea crystals. In this regard, the type and/or dimension of the urea crystals
that are formed can be controlled so that pores formed upon their removal have a certain
porous structure (e.g., dendritic, linear). In an embodiment, the tissue scaffold can include an
electroactive polymer to produce an electroactive tissue scaffold. In addition, the topography
of the tissue scaffold can be tailored to accomplish desired goals. For example, the
topography can be tailored using the substrate, where in an embodiment, the substrate is
designed so that a network of channels is formed through the tissue scaffold.
As mentioned above, embodiments of the disclosure provide for methods of
stimulating cells or tissue. An embodiment of the present disclosure includes introducing
cells to the tissue scaffold, where the tissue scaffold (and optionally a tissue or other cells)
and the cells are cultured in an appropriate medium. Subsequently, electrical stimulation can
be periodically applied to the cells to cause a desired outcome.
Electrical stimulation can include direct contact of the material with a power source
via a wire, wireless energy transfer, magnetic force, and the like. The term "periodically"
refers to applying the electrical stimulation at established time frames that may be at regular
or irregular time intervals on the time frames of seconds, hours, days, weeks, or months (e.g.,
about 1 s to 2 months, about 1 hour to 1 day, about 1 day to 1 month, or other the like)
depending upon the specific circumstances. In an embodiment, the impulses of the electrical
stimulation can last on the time frame of seconds, hours, or days (e.g., about 1 second to 1
day, about 10 seconds to 1 hour, about 1 minute to 12 hours, about 1 hour to 1 day, or the
like) depending upon the specific circumstances. In an embodiment, the electrical
stimulation can be in the range of millivolts to volts (e.g., about 10 mV to 10 volts, about 1
mV to 100 mV, or the like). The time frame, duration of electrical stimulation, and intensity
of the electrical stimulation can be designed based on particular circumstances and
requirements of a specific situation.
In an embodiment, the tissue scaffold can include one or more agents (e.g., a chemical
or biological agent), where the agent can be disposed indirectly or directly on the tissue
scaffold. In an embodiment, the agent can include, but is not limited to, a drug, a therapeutic
agent, a radiological agent, a small molecule drug, a biological agent (e.g., polypeptides (e.g.,
proteins such as, but not limited to, antibodies (monoclonal or polyclonal)), antigens, nucleic
acids (both monomeric and oligomeric), polysaccharides, haptens, sugars, fatty acids,
steroids, purines, pyrimidines, ligands, and aptamers) and combinations thereof, that can be
used to image, detect, study, monitor, evaluate, and the like. In an embodiment, the agent is
included in an effective amount to accomplish its purpose, where such factors to accomplish
the purpose are well known in the medical arts.
In general, the agent can be bound to the tissue scaffold by a physical, biological,
biochemical, and/or chemical association directly or indirectly by a suitable means. The term
"bound" can include, but is not limited to, chemically bonded (e.g., covalently or ionically),
biologically bonded, biochemically bonded, and/or otherwise associated with the material. In
an embodiment, being bound can include, but is not limited to, a covalent bond, a non-
covalent bond, an ionic bond, a chelated bond, as well as being bound through interactions
such as, but not limited to, hydrophobic interactions, hydrophilic interactions, charge-charge
interactions, pi-pi stacking interactions, combinations thereof, and like interactions."
While embodiments of the present disclosure are described in connection with the
Examples and the corresponding text and figures, there is no intent to limit the disclosure to
the embodiments in these descriptions. On the contrary, the intent is to cover all alternatives,




Bodily tissues are hierarchically structured composite materials with tissue-specific
properties that act as cues that dictate the behavior of cells that inhabit them, and such
properties can potentially be engineered into instructional tissue scaffolds to achieve similar
results [1-6]. Topographical control of cell alignment is clearly observable within
anisotropically aligned pores that are observed in bone, muscle, nerve and other tissues,
which motivates the development of novel methodologies of imparting biomimetic porous
structures within biomaterials [1-6].
Silk protein-based materials are produced by a number of different species (the most
widely studied being that of the domesticated B. mori silkworm) [5,7-10], many of which
display interesting mechanical properties and low immunogenicity, and have led to the
development of engineered silk-inspired proteins produced recombinantly [ 11-15], or silk-
inspired polymers produced by synthetic chemists [15]. Silk-based biomaterials are popular for
a variety of applications because of: (1) their ease of processing in a variety of different
solvents (including water, ionic liquids, formic acid, hexafluoroacetone hydrate and
hexafluoroisopropanol); (2) the morphologies that can be manufactured (fibers, films, foams,
hydrogels); and (3) their ease of chemical modification [7-15]. Silk-based biomaterials and
their composites are capable of controlled drug delivery, and of acting as cell adhesive tissue
scaffolds for a variety of different niches both in vitro and in vivo [7-15].
Although it is possible to employ 3D printing technologies to prepare porous
materials, it is challenging to fabricate porous structures accurately mimicking native tissues
[1-6]. The removal of sacrificial templates (e.g., colloidal crystals, ice crystals, electrospun
fibers) from a matrix is an alternative approach that allows the generation of hierarchically
organized pores in materials [1-6], potentially on the nanoscale [16]. Urea is an inexpensive,
non-toxic solid that self-assembles into supracolloidal crystals. The uncontrolled evaporation
of water from aqueous solutions of urea yields random networks of dendritic crystals, whereas
controlled use of urea seed crystals to initiate crystallization yields relatively well aligned
crystals over the length scale of a few hundred micrometers [17]. Zawko and coworkers
reported the use of urea to impart pores within photocrosslinkable biopolymer-based
hydrogels that typically have mechanical properties similar to soft, and fibroblasts cultured
within the gels were observed to align parallel to the fibrillar microstructure of the hydrogels
[17]. While entirely aqueous manufacturing processes are appealing, they restrict the
selection of materials used to those that are soluble in water (e.g., polysaccharides), and there
are many water insoluble polymers used in the clinic. Therefore we used a non-aqueous
solvent hexafluoroisopropanol (HFIP) to generate urea-templated polycaprolactone foams
[18]. We also reported a simple scalable methodology for aligning the supracolloidal crystals
that allows the generation of pores that were aligned over length scales of multiple
centimeters within which Schwann cells from the peripheral nervous system aligned [18].
In this Example, we explain the solvent interactions governing the solubility of urea
which enables us to expand the range of solvents compatible with our urea-based
supracolloidal crystal templating methodology, and thereby broadens the scope of polymers it
is compatible with. We also highlight the role of solvent interactions on the morphology of
the resulting supracolloidal crystals, and moreover, the role of polymer-porogen (silk-urea)
interactions on the morphology of the pores in the resulting biomaterials. Finally, we
demonstrate that it is possible to use our urea templating methodology to prepare silk protein-
based biomaterials with aligned pores that permit cell growth and alignment (Figure 1.1).
Results and Discussion
Urea Solubility in Non-Aqueous Solvents
A parameterized approach was used to investigate the ability of non-aqueous solvents
to dissolve urea. Solvent-solute interactions play an important role in supramolecular
chemistry which has led to quantitative studies of the role of solvents in self-assembly
processes [19-24]. The bulk properties (e.g., boiling point, density) or molecular level
properties (such as specific intermolecular forces) can be quantified and parameterized. Bulk
property parameters include the dielectric constant (ε) and Reichardt's parameter (Ε , a
measure of ionizing power). Molecular level parameters include the Hildebrand solubility
parameter, δ (expressed in terms of the total solubility parameter, δο, which is described by
the dispersion, polar, and hydrogen bonding parameters, , δρ, and δ¾ respectively. The
parameters δρ and δ are described in terms of a combined polar solubility parameter,
a
, and
the Kamlet-Taft parameters, pi* (a generalized polarity parameter), a (the ability to donate
hydrogen bonds), and β (the ability to accept hydrogen bonds). The effects of solvents on the
hierarchical assembly of supramolecular polymers in non-aqueous solvents have been studied
for self-assembling peptides, and while there was a general correlation between the ability of
supramolecular polymers to form and the polar solubility parameter, a [19-24], the precise
hydrogen-bonding nature of the solvent in terms of Kamlet-Taft parameters (i.e.,
deconvolution of the hydrogen bond donors and acceptors) was important to fully understand
the solvent effects [19-24]. Hydrogen bond donor solvents but not acceptors, played a key
role in disrupting amide-mediated self-assembly in non-aqueous solvents.
To generate highly porous biomaterials w e require the sacrificial template to be highly
soluble in the solvent used during polymer processing. Thus w e investigated the ability of a
variety of non-aqueous solvents to dissolve urea at a concentration of 100 mg/mL (see Table
1.1), an arbitrary concentration equivalent to the concentration of polymer, thereby assuring
the presence of pores with micrometer scale diameters in the resulting materials.
Boiling Surface
Solubility
Solvent ε Ε pi* a B point tension
of Urea
(°C) (niN/m)
Cyclohexane 2.10 0.006 0.00 0.00 0.00 80.7 25.0 I.S.
Toluene 2.38 0.099 0.49 0.00 0.11 110.6 28.5 I.S.
Chloroform 4.80 0.259 0.69 0.44 0.00 61.2 26.7 I.S.
Tetrahydrofuran 7.58 0.207 0.55 0.00 0.55 66.0 26.4 I.S.
Dichloromethane 8.93 0.309 0.73 0.30 0.00 39.6 26.5 I.S.
Ethyl acetate 36.6 0.18 0.55 0.00 0.45 77.1 23.8 I.S.
Acetonitrile 45.60 0.460 0.75 0.19 0.40 82.0 19.1 I.S.
Isopropanol 49.20 0.570 0.48 0.76 0.84 82.6 23.0 I.S.
Butanol 50.20 0.600 0.47 0.84 0.84 117.4 24.2 I.S.
Ethanol 51.90 0.650 0.54 0.86 0.75 78.4 22.3 I.S.
Methanol 55.40 0.760 0.60 0.98 0.66 64.7 22.5 s
Formic acid 57.70 0.830 0.65 1.23 0.38 100.8 37.7 s
Hexafluoroisopropanol 65.30 1.070 0.65 1.96 0.00 58.2 16.1 s
Hexafluoroacetone-3H 20 N.R. N.R. N.R. N.R. N.R. -26.0 N.R. s
Water 63.10 1.000 1.09 1.17 0.47 100.0 72.8 s
Table. 1.1. The properties of the non-aqueous solvents investigated for the
dissolution of urea at a concentration of 100 mg/mL. Solvent parameters:
dielectric constant (ε), Reichardt's parameter (ET), and Kamlet-Taft parameters,
pi*, , and β. (N.R.) Not reported in the literature; Hexafluoroacetone is a gas
and it evaporates readily from aqueous solutions; (IS.) insufficiently soluble; and
(S) sufficiently soluble.
The solubility of urea in the various solvents was clearly correlated to the parameters
describing the bulk properties of the solvent (i.e., the dielectric constant (ε) and Reichardt's
parameter (Ε )). Indeed, solvents with dielectric constants and Reichardt's parameters similar
to water were the most potent solvents for urea, and there was a threshold of dielectric
constants and Reichardt's parameters below which the urea was insoluble (ca. 55 and 0.75,
respectively). Interestingly, the Kamlet-Taft polarity parameters provided useful insight into
the importance of individual molecular level interactions on the solubility of urea in the
respective solvents. There was no clear correlation between the ability of a solvent to dissolve
urea and the generalized polarity parameter, pi*. While solvents capable of dissolving urea all
had pi* values of 0.60 or above, this was not a general rule: acetonitrile, chloroform, and
dichloromethane (with pi* values of 0.75, 0.69 or 0.73 respectively) were poor/non-solvents.
There was no correlation between the ability of a solvent to dissolve urea and its ability to
accept hydrogen bonds (β) . Hexafluoroisopropanol (β = 0) was an excellent solvent for urea
whereas cyclohexane (β = 0) was a non-solvent for urea. The Kamlet-Taft parameter that
gave the clearest insight into the ability of a solvent to dissolve urea was its ability to donate
hydrogen bonds (a), and all of the solvents capable of dissolving urea had a values of ca. 1 or
more. Although the solvent parameters for hexafluoroacetone hydrate are not reported in the
literature, the acidity of the hydrate (pKa = 6.58) make it a strong hydrogen bond donor
capable of dissolving urea [25]. The solvents presented are clearly not an exhaustive list of
those capable of dissolving urea at high concentrations, however our parameterized approach
to investigating the ability of solvents to dissolve urea should enable others to easily identify
other solvents for urea (or analogous sacrificial porogens).
Importantly, the solvents we found to be good solvents for urea (formic acid,
hexafluoroisopropanol, hexafluoroacetone hydrate) are suitable for the dissolution of a
variety of polymers (including clinically relevant polyesters, peptides, proteins,
polyurethanes, etc.) which significantly broadens the scope of biomaterials our methodology
would be applicable for.
The Role of Solvent Choice on the Morphology of the Sacrificial Supracolloidal Porogens
Of the non-aqueous solvents identified as being capable of dissolving urea (i.e.,
formic acid, hexafluoroacetone hydrate, hexafluoroisopropanol and methanol) we
investigated formic acid, hexafluoroacetone hydrate and hexafluoroisopropanol in more detail
(we omitted methanol because it is a non-solvent for silk and known to beta-sheet formation
in the silk) [8-15].
Solvent evaporation from aqueous solutions of urea yields dendritic crystals if
performed uncontrolled, or less dendritic and relatively well aligned crystals (over the length
scale of a few hundred micrometers) if crystallization is initiated in a controlled fashion prior
to evaporation using seeds of urea crystals [17]. Thus, we investigated urea crystallization
from non-aqueous solvents under both uncontrolled and controlled evaporation conditions.
Urea crystallization is controlled by the rate of evaporation of solvent from the solution of
urea (100 mg/mL). Uncontrolled urea crystallization experiments were carried out by simply
applying urea solutions to the surface of glass microscope slides and allowing the solvent to
evaporate. Preliminary experiments attempting to control the directionality of urea
crystallization were carried out by sealing the tip of a Pasteur pipette, adding a quantity of
urea solution into the Pasteur pipette and allowing the solvent to evaporate slowly from the
wide end.
Of the solvents investigated, formic acid was the solvent with the boiling point and
surface tension closest to those of water, and we observed that uncontrolled urea
crystallization yielded somewhat dendritic crystals, with sections that were relatively well
aligned over the length scale of a few hundred micrometers (Figure 1.2A). Urea crystals
formed from the uncontrolled evaporation of either hexafluoroacetone hydrate (Figure 1.2B)
or hexafluoroisopropanol (Figure 1.2C) were less dendritic and showed alignment over the
length scale of millimeters, although this was not free of defects. Interestingly, controlling the
evaporation of hexafluoroisopropanol yielded crystals that were aligned over the length scale
of centimeters (Figure 1.2D). Consequently, we conclude that the solvent-solute interactions
govern not only the solubility of the solute, but also the morphology of the supracolloidal
assemblies resulting from the evaporation of the solvent.
As the hierarchical supracolloidal assemblies act as sacrificial templates to generate
porous biomaterials, we believe that it should be possible to tune the properties of such
supracolloidal assemblies in a rational way that will enable the generation of biomaterials
instructing cells to assemble in complex biomimetic patterns (e.g., concentric lamellae
observed in cortical bone, or helicoidal multi-lamellar alignment of corneal stroma tissue).
Recent advances in supramolecular architectonics, particularly DNA-mediated interactions
that have programmable structures from the A to colloidal length scales suggest that we will
see the first examples of these in the near future [26-32]. Moreover, the rational design of the
constituent supramolecular building blocks [33-37] offers the prospect of precisely
positioning functional species (e.g., nanoparticles) that may deliver therapeutics with precise
spatial control, or sense and report changes in the properties of the surrounding tissues (e.g.,
clusters of nanoparticles whose optical properties change in response to chemical, electrical
or mechanical triggers), which may be of use both in vitro and perhaps also in vivo.
Supracolloidal Tempiation of Porous Silk Biomaterials
Urea is a well-known and widely utilized protein denaturant in aqueous solutions, and
denatures proteins by disrupting the intermolecular and intramolecular hydrogen bonding
interactions that cause proteins to fold or associate into hierarchical assemblies. While the
uncontrolled crystallization of urea alone from formic acid yielded somewhat dendritic
crystals with sections that were relatively well aligned over the length scale of a few hundred
micrometers, the co-crystallization of urea and silk from formic acid, followed by washing to
remove the urea, yielded silk-based films with dendritic crystal-templated pores with
dimensions of ca. 20 100 µιη (Figures 1.3A-B). Likewise, co-crystallization of urea and silk
from hexafluoroacetone hydrate followed by washing also yielded silk-based films with very
fine dendritic crystal-templated pores with dimensions of approximately 5-10 µιη in diameter
and up to 100 µιη in length (Figure 1.33C-D). Co-crystallization of urea and silk from either
hexafluoroisopropanol (Figure 1.3E) or water (Figure 1.3F) followed by washing yielded
foams with larger pore diameters (10-40 µιη) and lengths extending several hundred
micrometers. These results suggest that molecular level interactions between the polymer and
sacrificial template (in this case hydrogen bonding interactions between the silk and urea),
and bulk solvent parameters (e.g., boiling point) play a role in dictating the morphology of
the macroscopic pore structures within biomaterials generated in this fashion. Evidence for
which can be observed in the predominantly dendritic pore structures in foams derived from
formic acid and hexafluoroacetone hydrate instead of the more linear pore structures in foams
derived from hexafluorisopropanol or water. In the future we foresee prospects for tuning the
polymer-porogen interactions that will facilitate rational design of pore structure within
biomaterials (particularly if DNA-architectonics were employed) [26-32].
Finally, to demonstrate that the pores imparted to silk-based biomaterials by
supracolloidal assemblies of urea act as topographical guidance cues for cells cultured inside
them, we cultured human dermal fibroblasts in water-derived scaffolds for five days.
Obtaining images of the live cells inside the scaffolds using the common cell-permeant dye
Calcein AM was challenging because of the strong background fluorescence of the scaffolds,
however, it was possible to obtain markedly improved images of the cells inside the scaffolds
after fixing them and staining with 4',6-diamidino-2-phenylindole (DAPI) (nuclei) and Alexa
Fluor 488® Phalloidin (actin filaments), and we observed that the fibroblasts preferentially
aligned with the pores inside the scaffold (Figure 1.4).
Experimental Section
Materials
Unless otherwise stated, all chemicals for synthesis and physicochemical analysis
were of American Chemical Society (ACS) grade, purchased from Sigma-Aldrich (St Louis,
MO, USA) and used as received without further purification. Bombyx mori silkworm fibroin
was purchased from eBay. Reagents for cell culture were purchased from Invitrogen
(Carlsbad, CA, USA) unless otherwise noted.
Urea Crystallization from Non-Aqueous Solvents
Urea was added to a non-aqueous solvent at a concentration of 0.1 g/mL. Samples
were shaken in airtight containers (typically 15 or 50 mL centrifuge tubes) at 1000 rpm using
a Thermomixer C (Eppendorf International, Hauppauge, NY, USA) for 48 h after which they
were visually assessed to determine if the urea was soluble. Optically clear solutions were
pipetted onto glass microscope slides (width 2.5 cm, length 7.5 cm) using disposable transfer
pipettes. The solvent was allowed to evaporate in a fume hood at room temperature for 48 h
and then dried under vacuum in a desiccator for 24 to 48 h . Preliminary experiments
attempting to control the directionality of urea crystallization were carried out by sealing the
tip of a Pasteur pipette, pipetting 200 of solution into the vertical Pasteur pipette and
allowing the solvent to evaporate slowly from the wide end. Images are representative of at
least 3 locations on 3 samples.
Urea crystal Templating of Porous Silk-Based Films
Silk (2 g) and urea (2 g) were dissolved in either formic acid (20 mL) or
hexafluoroacetone trihydrate (20 mL). Samples were shaken in airtight centrifuge tubes (50
mL) at 1000 rpm using a Thermomixer C until the components had fully dissolved (typically
24 to 48 h). Optically clear solutions of urea were pipetted onto glass microscope slides
(width 2.5 cm, length 7.5 cm) using disposable transfer pipettes. The solvent was allowed to
evaporate in a fume hood at room temperature for 48 h and then dried under vacuum in a
desiccator for 24 to 48 h .
Silk-based samples were immersed in aqueous methanol (80% methanol) for 1 h to
assure that the silk was rendered water insoluble due to the formation of inter- and intra
molecular β-sheets, and then placed in a container of water to wash out urea and methanol.
The samples were washed with water for 3 days to remove any traces of urea, typically
exchanging the water every 3 h (i.e., ca. 24 times), after which they were dried under high
vacuum for 24 to 48 h .
Preparation of Silk-Based Tissue Scaffolds with Aligned Pores
Solutions of silk and urea in hexafluoroisopropanol were prepared as described in
Section 2.2. Polydimethylsiloxane (PDMS) templates [18] were placed on flat rigid surfaces,
and solutions of silk/urea were pipetted into the grooves using disposable transfer pipettes.
Glass microscope slides (width 2.5 cm, length 7.5 cm) were placed on top of the PDMS
templates and the solvent was allowed to evaporate (typically 144 h), after which the slides
were removed and the silk/urea composites were then dried under vacuum in a desiccator for
24 to 48 h. Samples were immersed in aqueous methanol (80% methanol) for 1 h to assure
that the silk was rendered water insoluble due to the formation of inter- and intra-molecular
β-sheets, and then placed in a container of water to wash out urea and methanol. The samples
were washed with water for 3 days to remove any traces of urea, typically exchanging the
water every 3 h (i.e., ca. 24 times), after which they were dried under high vacuum for 24 to
48 h. The resulting white silk-based tissue scaffolds had thicknesses of ca. 0.4 mm as
determined using high precision digital calipers (ThermoFisher Scientific, Waltham, MA,
USA), widths of ca. 2 mm, and pores aligned over lengths of up to 0.5 cm. Samples were cut
to lengths appropriate for the various subsequent experiments using a razor blade.
Optical Microscopy of Urea and Silk Materials
Brightfield images of crystals of urea cast from formic acid, hexafluoroacetone
hydrate and hexafluoroisopropanol, or porous silk-based materials were obtained using an
Olympus 1X70 inverted microscope (Olympus Corporation of the Americas Inc., Center
Valley, PA, USA) equipped with an Olympus DP80 dual color and monochrome digital
camera (a 1.4 megapixel Bayer mosaic color CCD camera) that was attached to the
microscope with a 0.63 B-mount. Image Analysis was performed using Olympus cellSens ®
imaging software, Version 1.11 (Olympus Corporation of the Americas Inc.). Images are
representative of at least 3 locations on 3 samples.
Scanning Electron Microscopy (SEM)
Images of porous silk-based materials obtained using a scanning electron microscope
(SEM). Samples were mounted on a SEM stub and sputter coated with Pt/Pd (15 nm) using a
Cressington 208 benchtop sputter coater (Cressington Scientific Instruments, Watford, UK).
All samples were imaged using a Zeiss Supra 40 VP field emission scanning electron
microscope. Images are representative of at least 3 locations on 3 samples.
In Vitro Cell Culture
Human dermal fibroblasts (HDF, Invitrogen) were cultured in high glucose
Dulbecco's Modified Eagle Medium (DMEM) supplemented with GlutaMAX™ Supplement
(Invitrogen), 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin antibiotic
(Invitrogen). Cells were maintained at 37 °C in humidified atmosphere of 5% CO2. HDF
were seeded on the silk scaffold after treatment in ethanol for 1 h. Samples were subsequently
rinsed three times in PBS and incubated in complete media before seeding. HDF were seeded
at a density of 50,000 cells/cm2 and cultured for 1 week. Calcein AM staining of live cells
was applied in accordance with the instructions supplied with the kit (Invitrogen).
To stain the actin filaments and nuclei within cells, HDF were fixed in 2.5%
paraformaldehyde in PBS at room temperature for 20 min, and then rinsed in PBS three times
for 5 min. Cells were permeabilized in ice cold acetone (Sigma) at -20 °C for 5-10 min, and
then rinsed in PBS three times. Samples were incubated in 4',6-diamidino-2-phenylindole
(DAPI) solution at 300 nM for 10 min and for 1 h in 1:1000 Alexa Fluor® 488 Phalloidin
(Invitrogen), followed by rinsing. Samples were imaged with a Keyence Fluorescence
Microscope BZ-X700 (Keyence Corporation of America, Itasca, IL, USA) with excitation
and emission filters at 495-518 nm for Alexa Fluor® 488 and 358-461 nm for DAPI. Images
are representative of at least 3 locations on 3 samples.
Conclusions
Porous biomaterials are widely used in drug delivery and tissue engineering. 3D
printing technologies are very promising for the preparation of porous biomaterials, however,
they tend to be expensive. The removal of sacrificial templates (e.g., colloidal crystals, ice
crystals, fibers) from a matrix is a comparatively low cost alternative that allows the
generation of hierarchically organized pores in biomaterials. Herein, we expand our studies
on the use of sacrificial supracolloidal templates for the generation of porous biomaterials.
We expand the scope of polymers that the methodology is compatible with by elucidating the
solvent interactions governing the solubility of urea. We highlight the role of solvent
interactions on the morphology of the resulting supracolloidal crystals. We also highlight the
role of polymer-urea interactions on the morpohology of the pores in the resulting
biomaterials. Finally, we demonstrate that it is possible to use our urea templating
methodology to prepare B. mori silk protein-based biomaterials with pores that human dermal
fibroblasts respond to by aligning with the long axis of the pores. We believe that our
methodology has potential for application in a variety of different tissue engineering niches in
which cell alignment is observed, including skin, bone, muscle and nerve; particularly when
combined with the potential to guide the directionality of the urea crystals over multiple
centimeters [18].
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Example 2 :
Bodily tissues are hierarchically structured composite materials with tissue-specific
chemical and topographical properties, and these tissue-specific properties are known to act
as cues (individually or in concert) that dictate the behavior of cells that inhabit them, and can
potentially be engineered into instructional tissue scaffolds to achieve similar results [1-15].
Further to these cues, endogenous electric fields have been shown to act as behavioral cues
during embryogenesis and wound healing, and devices that deliver exogenous electrical fields
to the brain, ear or eye are already used in the clinic [4,16-19].
The complex interplay of chemical, electrical and topographical cues dictate the
behavior of cells, and implantable biomaterials that act as instructional tissue scaffolds may
facilitate the regeneration of functional tissues [2,7,8,12]. Topographical control of cell
alignment is clearly observable within anisotropically aligned pores that are observed in bone
[20,21], cardiac [22-25], nerve [3] and other tissues [6,7,26,27], which motivates the
development of novel methodologies of imparting biomimetic porous structures within
biomaterials.
While 3D printing technologies have prospects for the generation of porous materials,
it is still challenging to fabricate porous structures that accurately mimic the chemical and
intricate microscale and nanoscale topographical properties of native tissues, although
solutions to these challenges are the subject of intense current research [28-31]. The removal
of sacrificial templates embedded within a matrix (e.g., colloidal crystals, ice crystals,
electrospun fibers) is another approach that allows the generation of hierarchically organized
pore structures within materials [6,22].
Urea is a cheap, non-toxic solid that self-assembles through hydrogen bonding
interactions (Figure 2.1). The evaporation of water from aqueous solutions of urea yields
dendritic crystals if performed uncontrolled, and seeds of urea crystals can initiate
crystallization in a controlled manner prior to solvent evaporation to obtain less dendritic and
relatively well aligned crystals over the length scale of a few hundred micrometers [32].
Zawko and coworkers reported the use of a sacrificial supramolecular polymer-based
crystal template (urea) to impart pores [32] within photocrosslinkable biopolymer-based
hydrogels that typically have mechanical properties similar to soft tissues such as those in the
central nervous system [33]. Uncontrolled urea crystallization in aqueous solutions of
photocrosslinkable biopolymers followed by crosslinking yielded hydrogels with dendritic
pores within them [32]. Carefully controlling the seeding of urea crystal formation followed
by crosslinking allowed the generation of pores that were less dendritic and relatively aligned
over the length scale of a few hundred micrometers. Interestingly, fibroblasts cultured within
the gels were observed to align parallel to the fibrillar microstructure of the hydrogels,
whereas keratinocytes did not display any preferential orientation in response to the
topographical cue [32].
Manufacturing materials using entirely aqueous processes, such as that described
above is an appealing prospect, but it limits the selection of the materials usable used to those
that are soluble in water (e.g., polysaccharides), and there are many devices used in the clinic
based on polymers that are insoluble in water (e.g., PCL). Here we report the use of urea-
based supramolecular polymer crystals as sacrificial templates in the preparation of porous
tissue scaffolds from non-aqueous solvents. Moreover, we report a simple scalable
methodology for aligning the supramolecular polymer crystals that allows the generation of
aligned pores within the matrix of biodegradable polymer; and demonstrate that the pores
serve as topographical cues to which cells respond by aligning. Generation of an
interpenetrating network of PPy within the scaffold renders the scaffolds electroactive and
facilitates the electrical stimulation of cells cultured on the scaffolds. These methodologies
are broadly applicable to a variety of materials, and represent broad platform technologies for
biomimetic tissue engineering.
Porous biomaterials are broadly applicable in tissue engineering [6,7,26,27,34], and
we sought to demonstrate that electroactive materials generated using our methodology can
electrically stimulate cells to yield a response [8,35-46]. Therefore, we used our
methodologies to manufacture electroactive PCL-based scaffolds with biomimetic
topographical properties, and showed that electrical stimulation of glial cells from the
peripheral nervous system (i.e., Schwann cells) cultured on the scaffolds upregulated the
production of nerve growth factor (NGF) which has been shown to promote peripheral nerve
regeneration in vivo [47-64].
Experimental Section
Materials
Unless otherwise stated, all chemicals for synthesis and physicochemical analysis
were of ACS grade, purchased from Sigma-Aldrich and used as received without further
purification. Reagents for cell culture were purchased from Invitrogen (Carlsbad, CA, USA)
unless otherwise noted. Neonatal rat Schwann cells isolated from sciatic nerves were
purchased from ScienCell (Carlsbad, CA, USA).
Preparation of polydimethylsiloxane (PDMS) Templates
A 50 W laser cutter (Universal Laser Systems model VLS6.60, Scottsdale, AZ) was
used to manufacture acrylic master templates with grooves 2 mm in depth, 2 mm in width
and 10 cm long (Figures 2.2A and 2.2B). Polydimethylsiloxane (PDMS) was prepared using
a Sylgard® 184 silicone elastomer kit in accordance with the manufacturer's protocol. The
PDMS precursors were mixed in a disposable plastic weigh boat using a disposable plastic 1
mL pipette tip prior to being slowly poured over the grooved acrylic templates housed in a
disposable container of aluminum foil. Thereafter this setup was stored under vacuum in a
desiccator for 4 days at room temperature to allow the PDMS to crosslink fully. The acrylic
templates were cut out of the resulting PDMS films using a razor blade and the PDMS was
peeled from the acrylic template allowing it to be reused (Figure 2.2C).
Preparation of PCL-Based Tissue Scaffolds with Aligned Pores
PCL (Mn 80 kDa, 1 g) and urea ( 1 g) were dissolved in hexafluoroisopropanol (10
mL). Samples were shaken in airtight centrifuge tubes (50 mL) at 1000 rpm using a
Thermomixer C (Eppendorf International, Hauppauge, NY) until the components had fully
dissolved (typically 24 to 48 h). PDMS templates were placed on flat rigid surfaces, and
optically clear hexafluoroisopropanol solutions of PCL/urea were pipetted into the grooves
using disposable transfer pipettes. Glass microscope slides (width 2.5 cm, length 7.5 cm)
were then placed on top of the PDMS templates (as depicted in Figure 2D) and the
hexafluoroisopropanol was allowed to evaporate (typically 72 h), after which the slides were
removed and the PCL/urea composites were placed in a container of water (100 mL). The
samples were washed with water to remove the urea, exchanging the water every 3 h for 3
days, after which they were dried under high vacuum. The dimensions of the resulting white
PCL-based tissue scaffolds had thicknesses of ca. 0.4 mm as were determined using high
precision digital calipers (ThermoFisher Scientific, Waltham, MA), widths of ca. 2 mm, and
pores aligned over lengths of up to 6.6 cm. Samples were cut to lengths, appropriate for the
various subsequent experiments, using a razor blade. The porosity of the samples can be
calculated from:
'
The samples had mass ratios 1:1 PCL:urea. The density of PCL is: 1.145 g/cm , and 1
g therefore occupies 0.8733 cm3. The density of urea is: 1.32 g/cm3; so 1 g occupies 0.7575
cm3. Assuming that all of the urea is leached during the washing process, the porosity is: 46.4
Preparation of Electroactive PCL-Based Tissue Scaffolds with Aligned Pores
Pyrrole was purified by passage over basic alumina. White PCL-based tissue scaffolds
with aligned pores were placed in disposable 50 mL centrifuge tubes containing a solution of
pyrrole (291 µ , [84 mM], 1 eq.) and PSS (Mn 70 kDa, 0.799 g, [84 mM], 1 eq.) in distilled
water (50 mL). Samples were sonicated for 5 minutes and cooled to 4 °C (for 1 hour).
Thereafter, ferric chloride (1.848 g, [228 mM], 2.7 eq.) was added. The samples were shaken
to assure dissolution of the ferric chloride and then incubated for a further 24 h at 4 °C. Black
electroactive tissue scaffolds with aligned pores were removed from the reaction mixture,
placed in fresh distilled water, sonicated for 5 min, and then exhaustively washed (to remove
monomers, oligomers and initiators) with deionized water until the water used to wash the
materials was clear, colorless and the pH was neutral (ca. 48 h). Electroactive tissue scaffolds
(PCL with an interpenetrating network of PPy and PSS) with aligned pores were dried under
high vacuum at 2 1 °C. Samples were cut to lengths appropriate for the various subsequent
experiments using a razor blade.
Scanning Electron Microscopy (SEM)
Images of porous PCL-based materials obtained using a scanning electron microscope
(SEM). Samples were mounted on a SEM stub and sputter coated with Pt/Pd (15 nm) using a
Cressington 208 benchtop sputter coater. All samples were imaged using a Zeiss Supra 40 VP
field emission SEM.
Electrical Sheet Resistance
The electrical sheet resistance of the electroactive tissue scaffolds with aligned pores
was measured in accordance with the method described by Schmidt [65] and Zhang [66]. In
short, resistance (R in Ω) was measured between the two silver electrodes using a digital
multimeter (DM-8A, Sperry Instrument, Milwaulkee, WI). Sheet resistance (Rs) in Ω/square
was calculated as follows:
-
where W is the sample width (in cm) and L is the distance between the two silver electrodes
(in cm). The electrodes were moved to different positions after each measurement, and the
resistance R was recorded in at least ten different positions on the materials.
Fourier Transform Infrared Spectroscopy (FTIR)
Infrared spectroscopy was carried out on the samples to confirm that the surface
chemistry of the scaffolds had changed after the growth of an interpenetrating network of PPy
and PSS within the PCL matrix. A Thermo Scientific Nicolet 380 FTIR Spectrometer
(Thermo Fisher Scientific Inc., USA) was used. Spectra were recorded in attenuated total
reflectance (ATR) mode at 2 1 °C with a 1 c 1 resolution and 128 scans (corrected for
background and atmosphere using OMNIC software provided with the spectrometer).
Samples were secured in position on the ATR crystal using the built-in clamp.
X-Ray Photoelectron Spectroscopy (XPS)
XPS was carried out on the samples to confirm that the surface chemistry of the
scaffolds had changed after the growth of an interpenetrating network of PPy and PSS within
the PCL matrix. XPS was performed on a Kratos Axis X-ray photoelectron spectrometer
(Kratos Analytical Ltd., Manchester, UK). The binding energy was calibrated using the C Is
photoelectron peak at 284.6 eV as a reference. The CasaXPS computer program was used for
peak fitting of the C Is and O l s peaks in the XPS spectra. The reported spectra are
representative of two measurements at different positions on a sample.
In VitroDegradation Study
Samples were incubated in PBS ( 1 mL) at 37 °C, in the absence or presence of
cholesterol esterase (4 units/mL, Sigma Aldrich, USA). At specific time points the buffer was
removed, the samples were carefully washed with deionized water. The samples were then
dried under high vacuum to obtain a dry weight. The buffer (with or without enzymes) was
replaced, and the mass of the film was recorded over a period of several days. Mass loss
profiles represent the average of at least five samples.
In Vitro Cell Culture
PCL-Based Tissue Scaffold Preparation and Sterilization
Commercially available tissue-culture treated Corning® Costar® tissue culture plates
were used for control experiments. Non-electroactive and electroactive PCL-based tissue
scaffolds with aligned pores were incubated in an aqueous solution of poly-D-lysine (PDL,
50 µg/mL) for 1hour and then washed thoroughly with sterile water to remove any weakly
adsorbed PDL (exchanging the water every 10 min for 1 h). Samples were inserted in
untreated polystyrene tissue culture plates and sterilized by incubation in 70% ethanol
followed by exposure to UV for 60 min.
In Vitro Culture of Schwann Cells
After sterilization, scaffolds were incubated for 30 min under 3 mm of medium.
Schwann cell growth medium was composed of: 25.5 mL of low glucose Dulbecco's
Modified Eagle Medium (DMEM);8.5 mL of GIBCO® Ham's F-12 Nutrient Mixture; 350
Penicillin Streptomycin (1% of the final volume); 350 µ N2 supplement (2% of the final
volume); Forskolin [5 µΜ ]; Neuregulin- ΐ (50 ng/niL). Medium was aspirated and replaced
prior to Schwann cell seeding at 5,000 cells/cm2 under 3 mm of medium, and incubated at 37
°C, 95% humidity, and 5% CO2. Cell viability before starting the experiment was determined
by the Trypan Blue (Sigma, USA) exclusion method, and the measured viability exceeded
95% in all cases. After 2 days the medium was aspirated, the scaffolds were washed gently
with PBS, and the cells were fixed with 4% paraformaldehyde in PBS for 15 min. The
scaffolds were washed again with PBS (3 1 mL) and stored at 4 °C until they were stained
and imaged.
Electrical Stimulation of Schwann Cells
Electrical stimulation of Schwann cells was achieved employing a custom built setup.
Non-conductive glass slides, polycarbonate wells (square polycarbonate blocks, thickness of
1 cm, sides of 2.5 cm, with square holes with sides of 0.9 cm cut out), [67,68] Dow Corning®
high vacuum grease, and medium binder clips (Staples®, Framingham, MA) were sterilized
by autoclaving. Holes were drilled into the sides of 10 cm polystyrene Petri dishes using a
Dremel saw (Lowes, Mooresfield, NC, USA), and the plates were sterilized by exposure to
UV for 60 min. Adhesive-backed copper tape (5 mm width, Ted Pella, Inc.), waterproof
Kapton® tape ( 1 cm width, Fisher Scientific, Waltham, MA, USA), wires and alligator clips
were sterilized by exposure to UV for 60 min.
Electroactive PCL-based tissue scaffolds with aligned pores (prepared as described in
2.1 1.1.) were placed on glass slides and secured in position with two thin strips of adhesive-
backed copper tape that were attached to the films, parallel to one another and separated by a
distance of ca. 4 cm. One face of the polycarbonate wells was coated with vacuum grease and
placed on the electroactive tissue scaffolds, greased side down, in contact with the glass slide.
A binder clip on either side of the well was used to secure this in position and render it water
tight. A strip of copper tape was run between the parallel copper strips attached to the
scaffolds and the ends of the slides as points of contact for the alligator clip-terminated wires
attached to the multipotentiostat (CH Instruments, Austin, TX, USA). The counter and
reference electrodes were connected together and clipped to copper tape on one side of the
slide, and the working electrode was clipped to copper tape on the other side of the slide.
Schwann cells were plated and cultured as described in section 2.13.3. A potential step of +50
mV/mm was placed across the substrate for the duration of 1 h [69-71], after which the wires
were disconnected and the substrates cultured as normal (see Figure 2.3).
Fluorescence Staining and Imaging of Cells
Cells fixed with paraformaldehyde were permeabilized with 0.1% Triton X-100
(Fluka) and 2% bovine serum albumin (BSA) in PBS buffer for 5 min, followed by blocking
with 2% BSA in PBS buffer for 30 min at room temperature. Actin filaments and cell nuclei
within cells were stained with Alexa Fluor 488 ® Phalloidin (Life Technologies, USA) for 30
min and 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, USA) for 5 min, respectively.
The cells were thereafter washed three times with PBS and stored at 4 °C until images were
acquired. Fluorescence images of cells were obtained using an Olympus 1X70 inverted
microscope equipped with an Olympus DP80 dual color and monochrome digital camera (a
1.4 megapixel Bayer mosaic color CCD camera) that was attached to the microscope with a
0.63 B-mount. Image Analysis was done using Olympus cellSens® imaging software, Version
1.1 1.
NGF secretion studies
Schwann cells were cultured under the conditions described above for 1 day, after
which electrical stimulation for 1 h was optionally applied; non-stimulated controls included
commercially available tissue-culture treated Corning® Costar® tissue culture plates, and non-
electroactive/electroactive PCL-based tissue scaffolds with aligned pores. Medium was
collected from the Schwann cell cultures immediately after electrical stimulation (0 h) and
thereafter in intervals of 12 h for 3 days. The medium was stored at -20 °C for no more than
1 week prior to use in the Rat NGF ELISA Kit (Insight Genomics, Falls Church, VA, USA).
ELISA kits were utilized in accordance with the protocol supplied with the kit, employing a
Synergy HT Multi-Mode Microplate Reader (Biotek US, Winooski, VT, USA).
Concentrations of NGF/mL were calculated based on standards supplied in the NGF ELISA
Kit. Differences in cell numbers over the 3 day period of the assay were negligible as
determined with an AlamarBlue® cell viability assay, and concentrations of NGF in pg/mL are
therefore presented uncorrected.
Results and Discussion
Controlled Crystallization of Urea-Based Supramolecular Polymers as Sacrificial Templates
or the Generation of Porous Biomaterials: Preparation and Characterization of PCL-Based
Tissue Scaffolds with Highly Aligned Pores
We chose to produce tissue scaffolds incorporating aligned pores. With this goal in
mind, we produced hard acrylic master templates with grooves with depths of 2 mm, widths
of 2 mm and lengths of 10 cm using a laser cutter (Figure 2.2A). Flexible PDMS analogues
were prepared by embedding the master template (Figure 2.2B) in a container with the PDMS
precursors, allowing them to crosslink and then peeling the flexible PDMS template (Figure
2C) away from the surface of the acrylic master template. The resulting flexible PDMS
templates with possessing grooves with widths and heights of 2 mm and lengths of 10 cm for
the solutions of urea/polymer/hexafluoroisopropanol (Figure 2.2C, left) had an open top upon
which a glass slide (width of 2.5 cm, length of 7.5 cm) was placed. The glass slide prevented
hexafluoroisopropanol evaporation from the top of the template and allowed
hexafluoroisopropanol evaporation only at either end of the glass slide-covered grooves
(Figure 2.2D). Such The PDMS templates facilitated controlled solvent evaporation,
preferential alignment of urea crystals within the grooves, and the resulting scaffolds to be
easily removed from the templates to allow the sacrificial urea template to be removed by
washing, yielding scaffolds with porosities of ca. 46.4 %.
PCL-based tissue scaffolds produced using this methodology had thicknesses of ca.
0.4 mm, widths of ca. 2 mm, and pores (with widths of 10s of micrometers as observed by
SEM, Figure 2.4A and 2.4B) aligned over lengths of up to 6.6 cm (ca. 88% of the length of
the glass slide used to cover the grooves), which are clinically relevant length scales [8,72]. It
is noteworthy that this would be straightforward to adapt to manufacture longer scaffolds
using longer flexible templates and covers, and that this a very simple and inexpensive
methodology well suited to laboratories across the world.
Preparation and Characterization of Electroactive PCL-Based Tissue Scaffolds with Aligned
Pores
Methodology for the Preparation of Electroactive PCL-Based Tissue Scaffolds
A simple method to reproducibly prepare electroactive PCL-based scaffolds was the
generation of an interpenetrating network of electroactive PPy within the non-electroactive
PCL matrix. The interpenetrating networks of PPy in PCL scaffolds were generated simply
by incubating the scaffolds in aqueous solutions of pyrrole(monomer, concentration < 84
mM, PSS(dopant counter ion, 1 molar equivalent) and ferric chloride (initiator, 2.7 molar
equivalents) for 24 h followed by exhaustive washing. [65, 73] This simple process
reproducibly produced mechanically stable electroactive tissue scaffolds with well-preserved
micrometer and nanometer scale features; indeed, we found that use of higher concentrations
of pyrrole (which is a good solvent for PCL) partially dissolved the PCL-based scaffolds, and
extra crosslinking and washing steps are necessary to circumvent this problem (which also
permits them to be sterilized by autoclaving) as reported by Yaszemski and co-workers [74-
77]. Non-electroactive PCL-based scaffolds were white, whereas the electroactive scaffolds
were black, and electron microscopy showed evidence of a slightly increased surface
roughness on the nanometer scale due to the presence of polyelectrolyte complexes of
positively charged PPy and negatively charged PSS interwoven with the PCL matrix (Figure
3C and 3D) [65].
Spectroscopic Analysis of Non-Electroactive and Electroactive PCL-Based Tissue Scaffolds
Comparison of infrared spectra recorded in ATR mode of the non-electroactive
scaffolds (Figure 2.5A) and the electroactive scaffolds (Figure 2.5B) confirmed the
successful generation of an interpenetrating network of polyelectrolyte complexes of
positively charged PPy and negatively charged PSS interwoven within the PCL matrix.
Indeed, the peaks observed in the spectra of the electroactive scaffolds at ca. 1543 and ca.
1480 cn 1 are characteristic of the antisymmetric and symmetric ring stretching modes
respectively (Figure 2.5B) [78,79]. In addition, comparison of X-ray photoelectron spectra of
the non-electroactive scaffolds (Figure 2.5C) and the electroactive scaffolds (Figure 2.5D)
provided further evidence of alterations to the surface chemistry of the materials. The low
intensity peak in the spectra at ca. 31 eV is the Na 2s and 2p peak (from NaCl), and the peak
at ca. 500 eV is the corresponding Auger transition of sodium. The peak at ca. 99 eV is the Si
2p peak (a combination of the Si 2p 1 and Si 2p3 peaks) from the underlying substrate. The
peaks at ca. 285 eV correspond to C Is, and the broad peak at ca. 53 1 corresponds to O Is (a
combination of C-0 at ca. 531 and C=0 at ca. 533) which all arise from the PCL backbone.
The appearance of peaks in the spectra of the electroactive scaffolds at ca. 400 eV (N Is) and
ca. 168 eV (S 2p) are characteristic of PPy and PSS, respectively (Figure 2.5D) [65,66],
confirming the successful generation of an interpenetrating network.
Electrical Properties of Electroactive PCL-Based Tissue Scaffolds
Generation of an interpenetrating network of polyelectrolyte complexes of PPy and
PSS within the non electroactive PCL-based scaffolds rendered them electroactive with sheet
resistances of ca. 68 kH/square, on the order of analogous PPy-PSS polyelectrolyte complex-
coated poly(lactic-co-glycolic acid) nanofibers (ca. 17 kH/square) [65] or PPy-heparin
polyelectrolyte complex-coated Dacron® 56 polyester fibers (ca. 16 kH/square) [66]. The
relatively low resistance of the PPy-modified poly(lactic-co-glycolic acid) or Dacron® 56
fibers is likely to be because the PPy is localized on the surface of the fibers [65], whereas the
interpenetrating networks of PPy-PSS and PCL would have PPy-PSS in the bulk of the PCL
and display some non-conductive PCL chains on the surface of the scaffolds [73].
In Vitro Degradation of Non-Electroactive and Electroactive PCL-Based Tissue Scaffolds
While in vitro degradation experiments do not accurately reproduce conditions that
materials encounter when implanted in vivo (particularly patient-specific immune responses
or the tissue-specific distribution of enzymes), they are useful to confirm the potential of
materials to degrade upon exposure to enzymes found in vivo. To demonstrate that
enzymatic/hydrolytic degradation of the non-electroactive and electroactive PCL-based tissue
scaffolds is possible, we incubated them in PBS in the absence or presence of a high
concentration of an enzyme known to hydrolyze ester bonds in polyesters, cholesterol
esterase (4 units/mL) [80-84]. When incubated in PBS for 12 days the masses of non-
electroactive and electroactive scaffolds did not change significantly (Figure 2.6A, 2.6B,
respectively) because hydrolysis of PCL occurs very slowly [85]. The presence of the
esterase increases the rate of hydrolysis, resulting in a notable mass loss, ca. 40% over 12
days, from the non-electroactive PCL-based scaffolds (Figure 2.6A) and ca. 50% from the
electroactive versions (Figure 2.6B). The presence of the electroactive polyelectrolyte complex
of PPy and PSS appears to increase the hydrophilicity of the scaffolds allowing the enzyme to
more easily access the PCL chains. The scaffolds are likely to degrade slowly if administered
in vivo (over the period of several years) in line with other PCL-based materials [86] leaving
behind the residual water insoluble polyelectrolyte complex of PPy and PSS that preclinical
trials have shown to be relatively non-immunogenic. Indeed, histological analyses of tissue in
the vicinity of polypyrrole-based tissue scaffolds implanted subcutaneously or
intramuscularly in rats showed immune cell infiltration comparable to FDA-approved
poly(lactic acid-co-glycolic acid) [87] or poly(D,L-lactide-co-glycolide) [87]. Similarly, there
was no significant inflammation in the vicinity of polypyrrole-based materials implanted in
the coronary artery of rats after 5 weeks [88], sciatic nerve guidance channels implanted in
rats after 8 weeks [89], or electrodes in rat brains after 3 or 6 weeks [90].
In Vitro Cell Culture Studies on Instructional PCL-Based Tissue Scaffolds
Topographical Instruction: Aligned Pores are a Topographical Cue that Cells Respond to by
Aligning
The anisotropic features are commonly observed in functional tissues (including bone,
cardiac, musculoskeletal and nervous tissues), and scaffolds with biomimetic architectures
perform well in the clinic [2,7,8,12]. We investigated the adhesion of rat primary Schwann
cells on the non-electroactive and electroactive PCL-based tissue scaffolds with highly
aligned pores. After 48 h in culture we observed that Schwann cells responded to the
topographical cue by aligning preferentially with the long axis of the pores in the scaffolds
(Figures 2.7A-B), which is promising for future studies either with scaffolds derived from
other polymers and using other cell types.
Electrical Instruction: Electrical Stimulation is a Cue that Schwann Cells Respond to by
Increasing the Excretion of Nerve Growth Factor (NGF)
The role of endogenous electrical fields in the development of the nervous system
motivated research into the application of exogenous electrical fields for therapeutic
purposes, and preclinical studies show that electrical stimulation of damaged peripheral
nerves for short periods of time (e.g., 1 h) improves their regeneration [18,69-71]. Electrical
stimulation is known to affect cells differently depending upon a variety of factors including
the cell type and species from which they were isolated, as discussed in detail in recent
reviews [18,19]. Electrical stimulation of Schwann cells has been shown to increase the
production of nerve growth factor (NGF) from Schwann cells cultured on electroactive
indium tin oxide-based substrates [91], PPy-based substrates [92] or poly(3,4-
ethylenedioxythiophene)-based substrates [93] or non-electroactive poly-L-Lysine-coated
glass substrates [94]. NGF is a protein that plays a role in the growth, maintenance and
survival of neurons. In fact, preclinical studies in rats showed that NGF promoted peripheral
nerve regeneration [47-64], encouraging the development of NGF drug delivery systems [95],
some of which are electrochemically triggered [96] and have the potential for regeneration of
the nervous system.
Electroactive scaffolds such as those we report here clearly have the potential to act
both as electrochemically-triggered drug delivery devices as well as instructive scaffolds that
enable electrical stimulation of cells. We focused on the latter, investigating the amount of
NGF expressed by rat Schwann cells when electrically stimulated (50 mV/mm) on the
electroactive PCL-based tissue scaffolds with aligned pores, and non-stimulated controls
including commercially available tissue-culture treated Corning® Costar® tissue culture plates,
and non-electroactive/electroactive PCL-based tissue scaffolds with aligned pores. The
concentration of NGF in the medium (in pg/mL) was determined using a Rat NGF ELISA Kit
(Insight Genomics, Falls Church, VA) immediately after electrical stimulation and thereafter
in intervals of 1 h for 3 days. There were no significant differences in NGF production by
Schwann cells in any of the non-stimulated controls over the 3 day study. In contrast to this,
after 48 hours in culture we observed that Schwann cells responded to the electrical cue and
increased production of NGF to ca. three times the amount produced by an equivalent
number of cells without electrical stimulation, a trend that was markedly more apparent during
the following 24 h (Figure 2.8). Such increases in NGF production have been shown to
encourage neurite outgrowth from neurons in a number of studies [97,98].
Our finding that cells respond not only to the topographical cue imparted through use
of urea-based supramolecular polymer crystal sacrificial templates, but also to the electrical
cue facilitated by an interpenetrating network of PPy shows the potential of our innovative
biomaterials to function not only as scaffolds with potential for nerve regeneration, but also
as platforms for the development of porous scaffolds for other tissues.
Conclusions
There is a need for biomaterials with biomimetic chemical and topographical
properties for application as tissue scaffolds. Likewise, materials that facilitate the application
of exogenous electrical fields have a variety of potential therapeutic applications. Here we
present a novel process to manufacture instructional tissue scaffolds with biomimetic
topographical properties and a process to render these scaffolds electroactive that allows
electrical stimulation of cells cultured on them.
Sacrificial supramolecular polymer-based crystals composed of urea were used to
generate pores within a matrix of a biodegradable polymer. We show that it is possible to
generate both dendritic and linear urea crystals dependent on the solvent used, and, moreover,
that co-crystallization of urea with a polymer controls the propensity of the urea to form
dendritic or linear crystals, thereby controlling the topography generated within the polymer
matrix. Additionally, we have developed a simple, inexpensive, scalable method of aligning
the supramolecular polymer-based crystals within the biodegradable polymer matrix,
allowing the preparation of scaffolds with macroscopic pores that are aligned over long,
clinically relevant distances on the order of centimeters. The pores act as topographical cues
to which rat Schwann cells responded by aligning.
We can prepare electroactive tissue scaffolds with biomimetic topographical
properties using simple chemistry that allows the electrical stimulation of Schwann cells
cultured on the scaffolds. This electrical cue increased the production of nerve growth factor
(NGF) to more than three times the amount produced by non-stimulated cells, which may
improve clinical outcomes during peripheral nerve regeneration.
Together, these simple, inexpensive methods represent a platform technology that
facilitates the development of porous electroactive biomaterials.
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It should be noted that ratios, concentrations, amounts, and other numerical data may
be expressed herein in a range format. It is to be understood that such a range format is used
for convenience and brevity, and thus, should be interpreted in a flexible manner to include
not only the numerical values explicitly recited as the limits of the range, but also to include
all the individual numerical values or sub-ranges encompassed within that range as if each
numerical value and sub-range is explicitly recited. To illustrate, a concentration range of
"about 0.1% to about 5%" should be interpreted to include not only the explicitly recited
concentration of about 0.1 wt% to about 5 wt%, but also include individual concentrations
(e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%)
within the indicated range. In an embodiment, the term "about" can include traditional
rounding according to significant figures of the numerical value. In addition, the phrase
"about 'x' to " includes "about 'x' to about 'y"\
Many variations and modifications may be made to the above-described
embodiments. All such modifications and variations are intended to be included herein
within the scope of this disclosure and protected by the following claims.
CLAIMS
We claim:
1. A method of forming a tissue scaffold, comprising:
mixing a solution including urea and a non-aqueous solvent with a polymer that is
soluble with the solvent to form a mixture;
disposing the mixture on a substrate; and
removing the solvent from the mixture to form a tissue scaffold.
2. The method of claim 1, further comprising: removing the urea from the tissue scaffold
to form a biodegradable porous tissue scaffold, wherein removal of the urea forms pores
within the tissue scaffold to form the biodegradable porous tissue scaffold.
3. The method of claim 1, wherein the non-aqueous solvent is selected from the group
consisting of: formic acid, trifluoroacetic acid, hexafluoroisopropanol, hexafluoroacetone
hydrate, methanol, ethanol, propanol, isopropanol, acetophenone, methoxyethanol,
ethanediol, 1,2-propanediol, 1,3 -propanediol, glycerol, glycerol monoacetate, glycerol
diacetate, methylacetate, ethylacetate, allyl alcohol, furfuryl alcohol, diacetone alcohol,
benzyl alcohol, cyclohexanol and a combination thereof.
4. The method of claim 1, wherein the polymer is insoluble in water.
5. The method of claim 4, wherein the polymer is selected from the group consisting of:
nylon, hydroxybutyric acids, polyanhydrides, polphosphazenes, polyphosphoesters,
polyethers, polysilanes, polysiloxanes, polyurethanes,) polycaprolactone, polyesters,
polyamides, PCL, PLLA, PLGA, lignins, polyalanine, oligoalanine, collagen, silk, cellulose,
chitin, chitosan, dextran, and a combination thereof.
6. The method of claim 1, further comprising an electroactive tissue scaffold by
polymerizing an electroactive polymer with the tissue scaffold.
7. The method of claim 6, further comprising: removing the urea from the electroactive
tissue scaffold to form a biodegradable electroactive porous tissue scaffold, wherein removal
of the urea forms pores within the tissue scaffold to form the biodegradable electroactive
porous tissue scaffold.
8. The method of claim 6, wherein the electroactive polymer is selected from the group
consisting of: polypyrrole, polyaniline, polythiophene, poly(3,4-ethylenedioxythiophene),
poly fluorenes, polyphenylenes, polypyrenes, polyazulenes, polynapthalenes, polyindoles,
polyazepines, poly(p-phenylene sulfide)s, poly(p-phenylene vinylene)s, polyfurans, and a
combination thereof.
9. The method of claim 1, wherein the substrate includes a network of channels, wherein
the mixture is disposed in the network of channels, wherein further comprising: removing the
substrate to form the tissue scaffold having a network of pores extending through the tissue
scaffold.
10. The method of claim 9, wherein the network of channels are aligned relative to one
another and each of the channels in the network of channels has a diameter of about 50 nm to
100 µιη and the length of about 1 cm to 10 cm.
11. The method of claim 9, further comprising: removing the urea from the tissue scaffold
to form a biodegradable porous tissue scaffold, wherein removal of the urea forms pores
within the tissue scaffold to form the biodegradable porous tissue scaffold.
12. The method of claim 11, wherein the pores formed from removal of the urea are of
the type selected from the group consisting of: dendritic, linear, and a combination thereof.
13. A structure, comprising:
a tissue scaffold including a polymer and urea, wherein the polymer is soluble in a
non-aqueous solvent selected from the group consisting of: formic acid, trifluoroacetic acid,
hexafluoroisopropanol, hexafluoroacetone hydrate, methanol, ethanol, propanol, isopropanol,
acetophenone, methoxyethanol, ethanediol, 1,2-propanediol, 1,3 -propanediol, glycerol,
glycerol monoacetate, glycerol diacetate, methylacetate, ethylacetate, allyl alcohol, furfuryl
alcohol, diacetone alcohol, benzyl alcohol, cyclohexanol and a combination thereof.
14. The structure of claim 13, wherein the polymer is not soluble in water.
15. The structure of claim 14, wherein the polymer is selected from the group consisting
of: nylon, hydroxybutyric acids, polyanhydrides, polphosphazenes, polyphosphoesters,
polyethers, polysilanes, polysiloxanes, polyurethanes, polycaprolactone, polyesters,
polyamides, PCL, PLLA, PLGA, lignins, polyalanine, oligoalanine, collagen, silk, cellulose,
chitin, chitosan, dextran, and a combination thereof.
16. The structure of claim 13, further comprising an electroactive polymer.
17. The structure of claim 16, wherein the electroactive polymer is selected from the
group consisting of: polypyrrole, polyaniline, polythiophene, poly(3,4-
ethylenedioxythiophene), poly fluorenes, polyphenylenes, polypyrenes, polyazulenes,
polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s, poly(p-phenylene
vinylene)s, polyfurans, and a combination thereof.
18. The structure of claim 13, wherein the urea is in the form of urea crystals, wherein the
urea crystals have a crystal structure selected from the group consisting of: dendritic, linear,
or a combination thereof.
19. The structure of claim 13, wherein the tissue scaffold includes a network of channels
that are aligned relative to one another and each of the channels in the network of channels
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